Future Clinical Setbacks In Phase III Programs Will Threaten Long Term Oncology Ambitions

Catalysts

About Summit Therapeutics

Summit Therapeutics is a biopharmaceutical company focused on developing and commercializing ivonescimab for cancer patients across multiple solid tumor indications.

What are the underlying business or industry changes driving this perspective?

• The large global market for checkpoint inhibitors and anti VEGF therapies, estimated by external sources at over US$100b, creates high expectations for ivonescimab as a potential platform drug. This can pressure management to keep expanding trials and indications even if future data are mixed, putting future R&D spend and earnings at risk.
• The high level of clinical activity around ivonescimab, with 15 Phase III trials and more than 4,000 patients treated in Summit or Akeso sponsored studies, raises the bar for future trial outcomes. Any future Phase III setbacks or less favorable data versus existing PD 1 regimens could weigh on the ability to translate the current program into sustainable revenue and margin growth.
• Summit is rapidly building commercial infrastructure ahead of potential approvals, including ramping commercial readiness and maintaining quarterly non GAAP operating expenses above US$100m. This may be difficult to support if future U.S. or ex China launches are slower than hoped, putting pressure on net margins and cash burn.
• Reliance on external collaborators and cooperative groups, including Akeso, GORTEC, Revolution Medicines and GSK, ties a meaningful part of Summit's future to partners' trial execution and decision making. Delays, reprioritizations or weaker than expected data in combination settings could limit revenue contribution from these programs while fixed costs remain in place.
• The company is concentrating heavily on oncology indications such as non small cell lung cancer, colorectal cancer and head and neck cancers where treatment standards continue to evolve. If future competitors reshape treatment patterns around new immunotherapies or antibody drug conjugates, Summit may need higher than expected commercial and R&D investment to defend share, weighing on operating expenses and earnings visibility.

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more pessimistic perspective on Summit Therapeutics compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
• Summit Therapeutics currently has no revenue. The bearish analysts are forecasting revenue to reach $104.6 million by March 2029.
• The bearish analysts are not forecasting that Summit Therapeutics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Summit Therapeutics's profit margin will increase from 0.0% to the average GB Biotechs industry of 12.5% in 3 years.
• If Summit Therapeutics's profit margin were to converge on the industry average, you could expect earnings to reach $13.1 million (and earnings per share of $0.01) by about March 2029, up from -$1.1 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $1.7 billion in earnings, and the most bearish expecting $-1.3 billion.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 973.0x on those 2029 earnings, up from -11.2x today. This future PE is greater than the current PE for the GB Biotechs industry at 16.2x.
• The bearish analysts expect the number of shares outstanding to grow by 4.4% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.07%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Ivonescimab already has 4 positive Phase III readouts, 2 approvals in China and use in over 60,000 treated patients in that market. Broader global acceptance over time could support meaningful revenue generation if approvals and reimbursement follow in major regions, with a direct effect on top line revenue and earnings.
• The very large long term market for checkpoint inhibitors and anti VEGF therapies, estimated by external sources at over US$100b globally, gives Summit a sizeable addressable pool in multiple solid tumors. This could underpin multi indication uptake of ivonescimab and support sustained revenue and margin expansion if the product sees wide clinical adoption.
• Summit reports a cash balance of US$713.4m and no debt at year end 2025, which provides flexibility to fund extensive Phase III programs, commercial build out and collaborations without immediate reliance on dilutive financing. This could support execution on growth plans and improve long term earnings visibility.
• The breadth of the ivonescimab program, with 15 Phase III trials across lung, colorectal, head and neck and other cancers plus more than 4,000 patients treated in Summit or Akeso sponsored trials, increases the chance that at least some indications become commercially meaningful. This could diversify revenue sources and support more stable net margins over time.
• Partnerships with Akeso, GORTEC, Revolution Medicines and GSK, alongside over 60 investigator sponsored trials and more than 45 scientific publications and presentations, embed ivonescimab within global oncology research over the long term. This can sustain clinical interest, support label expansion and contribute to higher revenue and earnings potential if combination regimens and new settings prove clinically useful.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for Summit Therapeutics is $11.76, which represents up to two standard deviations below the consensus price target of $29.06. This valuation is based on what can be assumed as the expectations of Summit Therapeutics's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $40.16, and the most bearish reporting a price target of just $11.76.
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $104.6 million, earnings will come to $13.1 million, and it would be trading on a PE ratio of 973.0x, assuming you use a discount rate of 7.1%.
• Given the current share price of $15.6, the analyst price target of $11.76 is 32.7% lower. Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.